IL102857A - Compositions for the sublingual or buccal administration of therapeutic agents which are degraded upon oral administration - Google Patents

Compositions for the sublingual or buccal administration of therapeutic agents which are degraded upon oral administration

Info

Publication number
IL102857A
IL102857A IL10285792A IL10285792A IL102857A IL 102857 A IL102857 A IL 102857A IL 10285792 A IL10285792 A IL 10285792A IL 10285792 A IL10285792 A IL 10285792A IL 102857 A IL102857 A IL 102857A
Authority
IL
Israel
Prior art keywords
sublingual
therapeutic agents
degraded
administration
compositions
Prior art date
Application number
IL10285792A
Other languages
English (en)
Other versions
IL102857A0 (en
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of IL102857A0 publication Critical patent/IL102857A0/xx
Publication of IL102857A publication Critical patent/IL102857A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL10285792A 1991-08-26 1992-08-18 Compositions for the sublingual or buccal administration of therapeutic agents which are degraded upon oral administration IL102857A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75084391A 1991-08-26 1991-08-26

Publications (2)

Publication Number Publication Date
IL102857A0 IL102857A0 (en) 1993-01-31
IL102857A true IL102857A (en) 1997-02-18

Family

ID=25019382

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10285792A IL102857A (en) 1991-08-26 1992-08-18 Compositions for the sublingual or buccal administration of therapeutic agents which are degraded upon oral administration

Country Status (14)

Country Link
US (1) US5284657A (de)
EP (1) EP0601053B1 (de)
JP (1) JPH06510046A (de)
KR (1) KR100256715B1 (de)
AT (1) ATE197126T1 (de)
AU (1) AU669856B2 (de)
CA (1) CA2103163C (de)
DE (1) DE69231536T2 (de)
DK (1) DK0601053T3 (de)
ES (1) ES2153362T3 (de)
GR (1) GR3035116T3 (de)
IL (1) IL102857A (de)
PT (1) PT100812B (de)
WO (1) WO1993003751A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5487898A (en) * 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
EP0831870A4 (de) * 1995-06-07 1998-09-16 Avmax Inc Die verwendung von essentiellen ölen zur erhöhung der bioverfügbarkeit von oral applizierten pharmaka
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
WO1996039995A1 (en) * 1995-06-07 1996-12-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
KR100277287B1 (ko) * 1995-09-25 2001-01-15 맨슨 하비 콜린 거대환 락톤 구충제 조성물
US6949264B1 (en) 1996-11-27 2005-09-27 Wm. Wrigley Jr. Company Nutraceuticals or nutritional supplements and method of making
EP0880969A1 (de) * 1997-05-28 1998-12-02 Applied Research Systems ARS Holdings N.V. Im physiologischem Medium schwerlösliche pharmazeutische Peptidezusammensetzungen
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
AU4894697A (en) 1997-10-01 1999-04-23 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
EP1510213B1 (de) 1997-11-10 2008-12-31 Strakan International Limited Penetrationsfördernde und irritationsvermindernde Systeme mit Testosteron
AU2870899A (en) * 1998-02-26 1999-09-15 Abbott Laboratories Oral formulation for hydrophilic drugs
AU1574900A (en) * 1998-12-04 2000-06-26 Provalis (Uk) Limited Pharmaceutical compositions containing insulin
US6586023B1 (en) 1998-12-15 2003-07-01 Wm. Wrigley Jr. Company Process for controlling release of active agents from a chewing gum coating and product thereof
US7163705B2 (en) * 1998-12-15 2007-01-16 Wm. Wrigley Jr. Company Coated chewing gum product and method of making
US6531114B1 (en) 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US6627234B1 (en) 1998-12-15 2003-09-30 Wm. Wrigley Jr. Company Method of producing active agent coated chewing gum products
US6242473B1 (en) 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US20020159956A1 (en) * 1999-04-06 2002-10-31 Ream Ronald L. Over-coated chewing gum formulations
US7935362B2 (en) * 1999-04-06 2011-05-03 Wm. Wrigley Jr. Company Over-coated product including consumable center and medicament
US6355265B1 (en) 1999-04-06 2002-03-12 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US6322806B1 (en) 1999-04-06 2001-11-27 Wm. Wrigley Jr. Company Over-coated chewing gum formulations including tableted center
US6773716B2 (en) 1999-04-06 2004-08-10 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US6426090B1 (en) * 1999-04-06 2002-07-30 Wm. Wrigley Jr. Company Over-coated product including tableted center and medicament
JP2003501404A (ja) 1999-06-04 2003-01-14 デルルックス ファーマシューティカル コーポレイション 薬剤の脱水粒子からなる製剤およびこれの調製方法
US6645535B2 (en) 1999-09-02 2003-11-11 Wm. Wrigley Jr. Company Method of making coated chewing gum products containing various antacids
US6569472B1 (en) 2000-09-01 2003-05-27 Wm. Wrigley Jr. Company Coated chewing gum products containing antacid and method of making
US6663849B1 (en) 2000-09-01 2003-12-16 Wm. Wrigley Jr. Company Antacid chewing gum products coated with high viscosity materials
US6541048B2 (en) 1999-09-02 2003-04-01 Wm. Wrigley Jr. Company Coated chewing gum products containing an acid blocker and process of preparing
US9253991B2 (en) 1999-09-20 2016-02-09 Jack Barreca Chewing gum with B vitamins
AU3885201A (en) * 1999-09-20 2001-04-24 Mastercare Diet and weight control gum and sucker
US9387168B2 (en) 1999-09-20 2016-07-12 Jack Barreca Chewing gum with tomatidine
US6572900B1 (en) 2000-06-09 2003-06-03 Wm. Wrigley, Jr. Company Method for making coated chewing gum products including a high-intensity sweetener
US7115288B2 (en) * 2000-06-09 2006-10-03 Wm. Wrigley Jr. Company Method for making coated chewing gum products with a coating including an aldehyde flavor and a dipeptide sweetener
US6444241B1 (en) 2000-08-30 2002-09-03 Wm. Wrigley Jr. Company Caffeine coated chewing gum product and process of making
US6579545B2 (en) 2000-12-22 2003-06-17 Wm. Wrigley Jr. Company Coated chewing gum products containing an antigas agent
EP1435984A1 (de) * 2001-10-19 2004-07-14 Maxim Pharmaceuticals, Inc. Verwendung von histamin zur behandlung von lebererkrankungen
WO2003055494A1 (en) * 2001-12-21 2003-07-10 Avmax, Inc. Use of ugt inhibitors to increase bioavailability
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
WO2004017913A2 (en) * 2002-08-22 2004-03-04 Nutrition 21, Inc. Arginine silicate inositol complex and use thereof
EP1575569B1 (de) 2002-12-13 2010-09-29 Durect Corporation Orale darreichungsform mit flüssigen hochviskosen trägersystemen
AU2003202112A1 (en) * 2003-01-30 2004-08-23 Council Of Scientific And Industrial Research Bioavailability enhancing activity of carum carvi extracts and fractions thereof
WO2004087190A1 (en) * 2003-04-02 2004-10-14 Genix Therapeutics Inc. Method for the treatment of prostate cancer
EP1660039B1 (de) * 2003-07-18 2016-09-28 Oakwood Laboratories L.L.C. Prävention von molekulargewichtreduktion des polymers, bildung von unreinheiten und gelierung in polymer-zusammensetzungen
JP4388322B2 (ja) * 2003-07-31 2009-12-24 花王株式会社 アポリポプロテインｄ分解抑制剤
US20050171192A1 (en) * 2003-12-11 2005-08-04 Gehlsen Kurt R. Use of histamine to treat bone disease
WO2005116657A2 (en) 2004-05-24 2005-12-08 Universität Zu Köln Identification of ergothioneine transporter and therapeutic uses thereof
WO2006009975A2 (en) * 2004-06-22 2006-01-26 Maxim Pharmaceuticals, Inc. Histamine to treat disorders affecting muscle function
RS52198B (sr) 2004-09-17 2012-10-31 Durect Corporation Rastvor lokalnog anestetika koji sadrži saib sa održivim delovanjem
US8030271B2 (en) * 2005-07-05 2011-10-04 Emisphere Technologies, Inc. Compositions and methods for buccal delivery of human growth hormone
WO2007011958A2 (en) 2005-07-15 2007-01-25 Emisphere Technologies, Inc. Intraoral dosage forms of glucagon
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20090054333A1 (en) * 2006-10-17 2009-02-26 Antonio Giordano Peptide inhibitors of cyclin-dependent kinase activity and uses thereof
ES2388355T3 (es) 2006-11-03 2012-10-11 Durect Corporation Sistemas de suministro transdémico que comprenden bupivacaína
EP2219622A1 (de) 2007-12-06 2010-08-25 Durect Corporation Verfahren zur behandlung von schmerzen, arthritischen zuständen oder entzündung im zusammenhang mit einer chronischen erkrankung
DK3085381T3 (en) 2008-05-21 2018-05-28 Ferring Bv ORODISPERSIBLE DESMOPRESSIN TO INCREASE THE INITIAL PERIOD OF SLEEP UNDERSTANDED BY NEW TURRY
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US9700650B2 (en) 2009-11-09 2017-07-11 Spotlight Technology Partners Llc Polysaccharide based hydrogels
CA2780274C (en) 2009-11-09 2018-06-26 Spotlight Technology Partners Llc Fragmented hydrogels
JP2016515523A (ja) 2013-03-15 2016-05-30 デュレクト コーポレーション 溶解変動性を低減させるためのレオロジー改質剤を有する組成物
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
MY205229A (en) 2016-07-06 2024-10-08 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer
GB2568849B (en) 2016-09-01 2022-08-10 Nutrition 21 Llc Magnesium biotinate compositions and methods of use
EP3873331A4 (de) 2018-11-02 2022-08-24 Nutrition 21, LLC Zusammensetzungen mit inositolstabilisierten argininsilikatkomplexen und inositol zur verbesserung der kognitiven funktion bei videospielern
IL294021A (en) 2019-12-16 2022-08-01 Nutrition 21 Llc Methods of production of arginine-silicate complexes
BR112022013784A2 (pt) 2020-01-13 2022-10-11 Durect Corp Sistemas de distribuição de fármacos de liberação prolongada com impurezas reduzidas e métodos relacionados
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244946A (en) * 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4382922A (en) * 1980-08-29 1983-05-10 The Salk Institute For Biological Studies Peptides affecting gonadal function
US4632979A (en) * 1984-06-18 1986-12-30 Tulane Educational Fund Therapeutic LHRH analogs
US4801577A (en) * 1987-02-05 1989-01-31 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
WO1990008537A1 (en) * 1989-02-06 1990-08-09 Abbott Laboratories Pharmaceutical compositions for oral administration

Also Published As

Publication number Publication date
AU669856B2 (en) 1996-06-27
WO1993003751A1 (en) 1993-03-04
CA2103163C (en) 1998-10-20
IL102857A0 (en) 1993-01-31
EP0601053A4 (en) 1996-07-17
ES2153362T3 (es) 2001-03-01
DE69231536T2 (de) 2001-06-13
AU2519392A (en) 1993-03-16
EP0601053B1 (de) 2000-10-25
US5284657A (en) 1994-02-08
JPH06510046A (ja) 1994-11-10
KR100256715B1 (ko) 2000-05-15
CA2103163A1 (en) 1993-03-04
PT100812A (pt) 1993-09-30
PT100812B (pt) 1999-07-30
DK0601053T3 (da) 2001-01-08
GR3035116T3 (en) 2001-03-30
ATE197126T1 (de) 2000-11-15
EP0601053A1 (de) 1994-06-15
DE69231536D1 (de) 2000-11-30

Similar Documents

Publication Publication Date Title
IL102857A (en) Compositions for the sublingual or buccal administration of therapeutic agents which are degraded upon oral administration
IL136285A0 (en) Pharmaceutical compositions containing an acid-labile active component
ATE306931T1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
ES2175413T5 (es) Formulaciones de aerosol
NO923142L (no) Cykliske peptider og anvendelse derav
ATE212846T1 (de) Bisphosphonat und anti-resorption agentien, enthaltende zusammensetzungen zur hemmung der knochenschwund
NO993467L (no) Granuler som innbefatter klavulanat og en eller flere eksipienter
CO4700456A1 (es) Formulaciones orales de etodolac s(+)-
AU3868997A (en) Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
NO963634L (no) Antihostepreparat inneholdende et antihostemiddel og benzydamin
IL105475A0 (en) Pharmaceutical compositions containing 1alpha,24(r)-dihydroxy-22(e)-dehydro-vitamin d3 for treating osteoporosis
CA2218643A1 (en) Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
ZA943648B (en) Medicament aerosol formulation based on fusafungine a process for its preparation and pharmaceutical compositions containing it
ES2184121T3 (es) Formulacion para el tratamiento y/o profilaxis de la demencia.
EP0820771A3 (de) Arzneimittel zur Behandlung von Neuropathien, das ein lipidlösliches Thiamin und eine Magnesiumverbindung enthält
IT1263222B (it) Composizione farmaceutica per la somministrazione attraverso le mucose.
AR018532A1 (es) Proteinas sustancialmente puras que contienen analogos de la beta-lipoproteina (blt); aislados de acidos nucleicos que codifican dichas proteinas yformulaciones farmaceuticas que comprenden las proteinas
DE3778826D1 (de) Bestaendige therapeutische zusammensetzungen, basierend auf hydrophobem pflanzlichem oel und verfahren zu ihrer herstellung.
AU658197B2 (en) New use of benzimidazoline-2-oxo-1-carboxylic acid derivatives
DE69208913D1 (de) 2-Oxindol-1-carboxamidderivat enthaltendes Arzneimittel zur rektalen Verabreichung
IT1254191B (it) Composizioni farmaceutiche stabili per la somministrazione orale di calcitonina

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees